Skip to content

A multicenter, randomized controlled study on the intervention of gua sha technique on chemotherapy-induced peripheral neurotoxicity symptoms

A multicenter, randomized controlled study on the intervention of gua sha technique on chemotherapy-induced peripheral neurotoxicity symptoms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001003
Enrollment
Unknown
Registered
2025-05-17
Start date
2025-02-19
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptoms of chemotherapy-induced peripheral neurotoxicity

Interventions

Interventional group:On the basis of the nursing method of the control group, the scraping technique was given

Sponsors

Guang 'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with malignant tumors by histological or cytopathological examination; 2. According to the "Neurology · Neurotoxicosis and Metabolic Diseases of the Nervous System" published by People's Military Medical Press in 2002, the patients had the main characteristics of CIPN symptoms, and had 1-3 CIPN symptoms after chemotherapy (assessed by NCI-CATAE 5.0 scale); 3. Have finished the first cycle of chemotherapy and are receiving the second or more cycles of chemotherapy; 4. KPS>= 60 points; 5.18 years < age <80 years; 6. The patient can actively cooperate with the intervention treatment, and the unconscious disorder can complete the questionnaire and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous neurological disease, diabetes and other diseases or conditions that can lead to peripheral neuropathy and similar symptoms; 2. Patients who had received scraping treatment within one week before enrollment; 3. Those who are receiving other medications that may cause neurotoxicity; 4. Patients with autoimmune diseases; 5. People with mental illness or participating in other clinical trials; 6. Complicated with serious heart, liver and kidney dysfunction; 7. Abnormal bleeding and coagulation function; 8. Local skin inflammation, scars, damage; 9. Allergic to paraffin oil; 10. Contraindications of other scraping techniques.

Design outcomes

Primary

MeasureTime frame
EORTC QLQ-CIPN 20 score on the CIPN Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer;

Secondary

MeasureTime frame
Numerical Rating Scale; EORTC QLQ-c30 (V3.0) was used to evaluate the quality of life of cancer patients.;Motor nerve conduction velocity;Activity of Daily Living;sensory nerve conduction velocity;

Countries

China

Contacts

Public ContactGuo Jing

Guang 'anmen Hospital, China Academy of Chinese Medical Sciences

393014377@qq.com+86 136 1116 3517

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026